Vaccine News and Research

Latest Vaccine News and Research

IRX Therapeutics raises $8M to further develop pipeline of cancer vaccine candidates

IRX Therapeutics, a developer of novel immunomodulators to treat cancer and viral diseases, today announced that it has raised $8 million through a note offering to existing shareholders. The new funding will be used to further develop its pipeline of cancer vaccine candidates, including its lead product, IRX-2. IRX Therapeutics has now raised a total of more than $80 million in private financing.

17 Jun 2010

Meningococcal disease in infants: A potentially difficult and serious diagnosis

An article published in the May 2010 edition of Postgraduate Medicine documents a case study where a previously healthy, 15-week-old male infant was misdiagnosed and died of meningococcal disease. Initially the patient showed signs of the common cold and was treated as such, but symptoms worsened and he was admitted to the hospital emergency department.

16 Jun 2010

Soligenix signs common stock purchase agreements with existing and new investors

Soligenix, Inc., a late-stage biopharmaceutical company, announced today that it has entered into common stock purchase agreements with both existing and new investors totaling approximately $5.16 million. Soligenix's North American commercial partner, Sigma-Tau Pharmaceuticals, Inc., participated in this financing.

16 Jun 2010

Minapharm Pharmaceuticals acquires 95% of the share capital of ProBioGen

ProBioGen AG announced today that Minapharm Pharmaceuticals, Cairo, has completed the acquisition of 95 % of the share capital of ProBioGen, an internationally renowned German cell line development and contract manufacturing specialist. The total purchase price of EUR 30.4 million includes earn-out payments which are conditional upon the achievement of defined milestones.

16 Jun 2010

FDA unveils safety reports on recently approved drugs, biologics

The U.S. Food and Drug Administration today unveiled a new source of information for patients and health care professionals on the safety of recently approved drugs and biologics.

16 Jun 2010

Microneedle skin patches as effective as hypodermic needles for flu vaccination

Flu vaccine delivered through skin patches containing microneedles has proven at least as effective at preventing influenza in mice as intramuscular, hypodermic flu immunization.

16 Jun 2010

Vaccination against 2009 H1N1 influenza virus may also protect against 1918 Spanish influenza virus

Researchers at Mount Sinai School of Medicine have determined people who were vaccinated against the 2009 H1N1 influenza virus may also be protected against the lethal 1918 Spanish influenza virus, which killed more than 50 million people worldwide. The new findings are published in the current issue of Nature Communications.

16 Jun 2010

Acclaimed virologist delivers the 2010 Leeuwenhoek prize lecture

Acclaimed virologist Robert Webster, Ph.D., of St. Jude Children's Research Hospital, presented the 2010 Leeuwenhoek prize lecture today, a prestigious recognition awarded by the Royal Society in London.

16 Jun 2010

Cyntellect to provide LEAP Cell Processing Workstation to Salk Institute for Biological Studies

Cyntellect, Inc., a privately-held life sciences company commercializing products to advance the study of cell biology, stem cell research, biopharmaceutical production, and drug discovery, has entered into an agreement with the Salk Institute for Biological Studies to provide its researchers with the LEAP™ Cell Processing Workstation.

16 Jun 2010

Alexion's Soliris may benefit patients with thrombotic microangiopathy from uncontrolled complement activation

Researchers reported today that Soliris® (eculizumab), a first-in-class terminal complement inhibitor developed by Alexion Pharmaceuticals, Inc., may provide clinical benefits to patients with thrombotic microangiopathy (TMA) resulting from uncontrolled complement activation. TMA, the formation of blood clots in capillaries and small arteries, can lead to life-threatening damage in multiple organs including kidney failure, thrombocytopenia (abnormally low platelet count) and anemia.

15 Jun 2010

Inovio commences immunization in U.S. Phase I clinical trial of SynCon H5N1 influenza DNA vaccine

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that it has immunized its first subject in a U.S. Phase I clinical trial to evaluate its SynCon™ H5N1 (avian) influenza DNA vaccine, VGX-3400X.

15 Jun 2010

First patient treated in multicentre Phase I clinical trial of SCIB1 DNA ImmunoBody vaccine for melanoma

Scancell Holdings Plc,, the developer of therapeutic cancer vaccines, today announces the enrolment and treatment of the first patient in its multicentre Phase I clinical trial of SCIB1, its DNA ImmunoBody® vaccine being developed for the treatment of melanoma. The trial will evaluate the safety and tolerability of SCIB1 in patients with late stage melanoma.

15 Jun 2010

New research evaluating substantial disease burden of PNH presented at European Hematology Association

Alexion Pharmaceuticals, Inc. today announced new research evaluating the substantial disease burden of paroxysmal nocturnal hemoglobinuria, an ultra-rare blood disorder, in patients worldwide. The International PNH Registry, involving 580 patients from 99 sites in 14 countries as of May 2010, found that the debilitating symptoms and life-threatening complications of PNH are similar across patient populations around the world.

14 Jun 2010

Monoclonal antibodies induce long-lasting, protective antiviral immune response

Monoclonal antibodies are the largest class of biotherapeutic drugs. When administered to infected organisms to blunt the propagation of pathogenic viruses, they may also induce a long-lasting and protective antiviral immune response similar to that achieved by vaccination. These results obtained in mice by the "Oncogenèse et Immunothérapie" group at the Institut de Génétique Moléculaire de Montpellier (CNRS/Universités Montpellier 1 and 2), have been published on 10 June in PLoS Pathogens.

14 Jun 2010

Children get MRI tests for reasons unrelated to benign anomalies: Study

Pediatricians whose patients undergo "routine" brain MRIs need a plan to deal with findings that commonly reveal unexpected-but-benign anomalies that are unlikely to cause any problem, reports a research team led by Johns Hopkins Children's Center investigators.

14 Jun 2010

ARCA receives approval to commence enrollment of first therapeutic trial using HIV vaccine candidate

News on the progress of a new trial may give new hope to patients with HIV who are dependent on anti-HIV drugs. The AIDS Research Consortium of Atlanta has received approval to begin enrollment of the first therapeutic trial ever conducted using a promising HIV vaccine candidate from Atlanta-based, GeoVax Inc, a biotechnology company that creates, develops and tests innovative HIV/AIDS vaccines.

14 Jun 2010

Scientists manipulate simple bacteria into constructing internal compartments for biofuels, vaccines

Scientists at the University of Kent and University College Cork have manipulated simple bacteria into constructing internal compartments where biofuels and vaccines can be produced.

14 Jun 2010

Researchers transform yellow fever vaccine to fend off mosquito borne parasites that cause malaria

There is no vaccine for malaria, which sickens almost a quarter of a billion people each year and kills a child every 30 seconds. That could be changing: researchers at The Rockefeller University have genetically transformed the yellow fever vaccine to prime the immune system to fend off the mosquito borne parasites that cause the disease.

14 Jun 2010

Capitol Hill briefing addresses neglected tropical diseases

At a Global Network for Neglected Tropical Diseases (NTD) briefing, held in conjunction with the Congressional Malaria and NTD Caucus in Washington, D.C. on Thursday, "U.S. researchers, pharmaceutical companies and government officials [said] they are making progress in an effort to curb [NTDs], but that they need more money and outside help," VOA News.

14 Jun 2010

ACIP's new immunization guidelines for upcoming year

Summer is all about barbeques and lazy days at the pool. It's also a good time to start thinking about preparing for flu season, and the vaccinations you or your child may need for the upcoming year, says Carrie Maffeo, a professor of pharmacy at Butler University, who specializes in immunizations.

14 Jun 2010

Vaccine News and Research

Latest Vaccine News and Research

IRX Therapeutics raises $8M to further develop pipeline of cancer vaccine candidates

Meningococcal disease in infants: A potentially difficult and serious diagnosis

Soligenix signs common stock purchase agreements with existing and new investors

Minapharm Pharmaceuticals acquires 95% of the share capital of ProBioGen

FDA unveils safety reports on recently approved drugs, biologics

Microneedle skin patches as effective as hypodermic needles for flu vaccination

Vaccination against 2009 H1N1 influenza virus may also protect against 1918 Spanish influenza virus

Acclaimed virologist delivers the 2010 Leeuwenhoek prize lecture

Cyntellect to provide LEAP Cell Processing Workstation to Salk Institute for Biological Studies

Alexion's Soliris may benefit patients with thrombotic microangiopathy from uncontrolled complement activation

Inovio commences immunization in U.S. Phase I clinical trial of SynCon H5N1 influenza DNA vaccine

First patient treated in multicentre Phase I clinical trial of SCIB1 DNA ImmunoBody vaccine for melanoma

New research evaluating substantial disease burden of PNH presented at European Hematology Association

Monoclonal antibodies induce long-lasting, protective antiviral immune response

Children get MRI tests for reasons unrelated to benign anomalies: Study

ARCA receives approval to commence enrollment of first therapeutic trial using HIV vaccine candidate

Scientists manipulate simple bacteria into constructing internal compartments for biofuels, vaccines

Researchers transform yellow fever vaccine to fend off mosquito borne parasites that cause malaria

Capitol Hill briefing addresses neglected tropical diseases

ACIP's new immunization guidelines for upcoming year

Event guide: 3rd mRNA Process Development & Manufacturing Europe eBook

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Vaccine News and Research

Latest Vaccine News and Research

Event guide: 3rd mRNA Process Development & Manufacturing Europe eBook

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Newsletters you may be interested in